A multicentre, non-interventional, cohort analysis describing the patients’ experience focusing on safety events among metastatic hormone-sensitive prostate cancer patients treated with Androgen Receptor Pathway Inhibitors (ARPIs) followed through a Telemonitoring tool funded by the French national healthcare insurance complemented with a chart review (ESPERANTO)